A Real-World, Prospective, Observational Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto®) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
Overview
- Phase
- N/A
- Intervention
- Rivaroxaban (Xarelto,Bay 59-7939)
- Conditions
- Non-valvular Atrial Fibrillation (NVAF)
- Sponsor
- Bayer
- Enrollment
- 504
- Locations
- 1
- Primary Endpoint
- Incidence of treatment-emergent AEs
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under real-life conditions.
The study will be conducted in routine clinical practice settings. Approximately 1000 patients from India will be enrolled in this study. Patients will be observed for maximum period of 12 months after the start of Xarelto treatment or until it is no longer possible (e.g. lost to follow-up, death, withdrawal) before the end of the observation period.
The decision by the investigator to start with of Xarelto must be independent of the inclusion of a patient to the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient should be an adult female or male, ≥18 years of age;
- •Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for prevention of stroke or systemic embolism per investigator's routine treatment practice;
- •Patient should not have received rivaroxaban in the past;
- •Patient/patient's legally acceptable representative should be willing to provide written informed consent.
Exclusion Criteria
- •Patient has contraindications to receive rivaroxaban therapy according to local prescribing information;
- •Patient is receiving anticoagulant therapy for indication other than NVAF and that needs to be continued as per discretion of treating physician;
- •Patient is participating in an investigational program with interventions outside of routine clinical practice.
Arms & Interventions
Treatment
Rivaroxaban treatment-naïve patients, at least 18 years of age and presenting with NVAF will be considered eligible for participation in this study only after the decision to treat with rivaroxaban has been made by the treating physician.
Intervention: Rivaroxaban (Xarelto,Bay 59-7939)
Outcomes
Primary Outcomes
Incidence of treatment-emergent AEs
Time Frame: Up to 18 months
Incidence of major bleeding events
Time Frame: Up to 18 months
Major bleeding events include: * Fatal bleeding * Symptomatic bleeding in a critical area or organ * Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. * Hemoglobin level; or * Need for transfusion of packed red blood cells or whole blood.
Incidence of all-cause death
Time Frame: Up to 18 months
Deaths will be adjudicated as either vascular (e.g., due to stroke, embolism, myocardial infarction, or arrhythmia) or non-vascular (e.g., malignancy or infection).
Incidence of treatment-emergent SAEs
Time Frame: Up to 18 months
Secondary Outcomes
- Non-major bleeding events(Up to 18 months)
- AE rates in the different NVAF risk factor categories(Up to 18 months)
- Incidence of symptomatic thromboembolic events(Up to 18 months)
- Treatment persistence with rivaroxaban(Up to 18 months)
- SAE rates in the different NVAF risk factor categories(Up to 18 months)